Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients.

Gabizon AA, Tahover E, Golan T, Geva R, Perets R, Amitay Y, Shmeeda H, Ohana P.

Invest New Drugs. 2020 Jan 18. doi: 10.1007/s10637-020-00897-3. [Epub ahead of print]

PMID:
31955309
2.

Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience.

Tahover E, Bar-Shalom R, Sapir E, Pfeffer R, Nemirovsky I, Turner Y, Gips M, Ohana P, Corn BW, Wang AZ, Gabizon AA.

Front Oncol. 2018 Nov 26;8:544. doi: 10.3389/fonc.2018.00544. eCollection 2018.

3.

Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA).

Patil Y, Shmeeda H, Amitay Y, Ohana P, Kumar S, Gabizon A.

Nanomedicine. 2018 Jun;14(4):1407-1416. doi: 10.1016/j.nano.2018.04.011. Epub 2018 Apr 19.

PMID:
29680672
4.

Characterization of Pegylated Liposomal Mitomycin C Lipid-Based Prodrug (Promitil) by High Sensitivity Differential Scanning Calorimetry and Cryogenic Transmission Electron Microscopy.

Wei X, Patil Y, Ohana P, Amitay Y, Shmeeda H, Gabizon A, Barenholz Y.

Mol Pharm. 2017 Dec 4;14(12):4339-4345. doi: 10.1021/acs.molpharmaceut.6b00865. Epub 2017 Oct 30.

PMID:
28045540
5.

Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy.

Tian X, Warner SB, Wagner KT, Caster JM, Zhang T, Ohana P, Gabizon AA, Wang AZ.

Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):547-55. doi: 10.1016/j.ijrobp.2016.06.2457. Epub 2016 Jul 1.

PMID:
27681751
6.

Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.

Patil Y, Amitay Y, Ohana P, Shmeeda H, Gabizon A.

J Control Release. 2016 Mar 10;225:87-95. doi: 10.1016/j.jconrel.2016.01.039. Epub 2016 Jan 22.

PMID:
26809007
7.

Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil(®)): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in Tissues.

Amitay Y, Shmeeda H, Patil Y, Gorin J, Tzemach D, Mak L, Ohana P, Gabizon A.

Pharm Res. 2016 Mar;33(3):686-700. doi: 10.1007/s11095-015-1819-7. Epub 2015 Nov 16.

PMID:
26572644
8.

Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.

Golan T, Grenader T, Ohana P, Amitay Y, Shmeeda H, La-Beck NM, Tahover E, Berger R, Gabizon AA.

Cancer Med. 2015 Oct;4(10):1472-83. doi: 10.1002/cam4.491. Epub 2015 Jul 14.

9.

Noninvasive cardiac monitoring in pregnancy: impedance cardiography versus echocardiography.

Burlingame J, Ohana P, Aaronoff M, Seto T.

J Perinatol. 2013 Sep;33(9):675-80. doi: 10.1038/jp.2013.35. Epub 2013 May 16.

10.

The increasing complexity of the oncofetal h19 gene locus: functional dissection and therapeutic intervention.

Matouk I, Raveh E, Ohana P, Lail RA, Gershtain E, Gilon M, De Groot N, Czerniak A, Hochberg A.

Int J Mol Sci. 2013 Feb 21;14(2):4298-316. doi: 10.3390/ijms14024298.

11.

H19-promoter-targeted therapy combined with gemcitabine in the treatment of pancreatic cancer.

Sorin V, Ohana P, Gallula J, Birman T, Matouk I, Hubert A, Gilon M, Hochberg A, Czerniak A.

ISRN Oncol. 2012;2012:351750. doi: 10.5402/2012/351750. Epub 2012 Jun 3.

12.

Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer.

Hanna N, Ohana P, Konikoff FM, Leichtmann G, Hubert A, Appelbaum L, Kopelman Y, Czerniak A, Hochberg A.

Cancer Gene Ther. 2012 Jun;19(6):374-81. doi: 10.1038/cgt.2012.10. Epub 2012 Apr 13.

PMID:
22498722
13.

Regional therapy with DTA-H19 vector suppresses growth of colon adenocarcinoma metastases in the rat liver.

Sorin V, Ohana P, Mizrahi A, Matouk I, Birman T, Hochberg A, Czerniak A.

Int J Oncol. 2011 Dec;39(6):1407-12. doi: 10.3892/ijo.2011.1171. Epub 2011 Aug 18.

PMID:
21874233
14.

Aerosolized BC-819 inhibits primary but not secondary lung cancer growth.

Hasenpusch G, Pfeifer C, Aneja MK, Wagner K, Reinhardt D, Gilon M, Ohana P, Hochberg A, Rudolph C.

PLoS One. 2011;6(6):e20760. doi: 10.1371/journal.pone.0020760. Epub 2011 Jun 8.

15.

The contribution of heart disease to pregnancy-related mortality according to the pregnancy mortality surveillance system.

Burlingame J, Horiuchi B, Ohana P, Onaka A, Sauvage LM.

J Perinatol. 2012 Mar;32(3):163-9. doi: 10.1038/jp.2011.74. Epub 2011 Jun 9.

PMID:
21660084
16.

Suicide activation in a 5-fluorouracil resistant colon cancer model in vitro.

Mader RM, Kalipciyan M, Ohana P, Hochberg A, Steger GG.

Int J Clin Pharmacol Ther. 2011 Jan;49(1):69-70. No abstract available.

PMID:
21176733
17.

Targeting diphtheria toxin and TNF alpha expression in ovarian tumors using the H19 regulatory sequences.

Mizrahi A, Hochberg A, Amiur S, Gallula J, Matouk I, Birman T, Levy T, Ladimir S, Ohana P.

Int J Clin Exp Med. 2010 Sep 21;3(4):270-82.

18.

Use of H19 Gene Regulatory Sequences in DNA-Based Therapy for Pancreatic Cancer.

Scaiewicz V, Sorin V, Fellig Y, Birman T, Mizrahi A, Galula J, Abu-Lail R, Shneider T, Ohana P, Buscail L, Hochberg A, Czerniak A.

J Oncol. 2010;2010:178174. doi: 10.1155/2010/178174. Epub 2010 Oct 28.

19.

Treatment of ovarian cancer ascites by intra-peritoneal injection of diphtheria toxin A chain-H19 vector: a case report.

Mizrahi A, Czerniak A, Ohana P, Amiur S, Gallula J, Matouk I, Abu-Lail R, Birman T, Hochberg A, Levy T.

J Med Case Rep. 2010 Jul 27;4:228. doi: 10.1186/1752-1947-4-228.

20.

The oncofetal H19 RNA connection: hypoxia, p53 and cancer.

Matouk IJ, Mezan S, Mizrahi A, Ohana P, Abu-Lail R, Fellig Y, Degroot N, Galun E, Hochberg A.

Biochim Biophys Acta. 2010 Apr;1803(4):443-51. doi: 10.1016/j.bbamcr.2010.01.010. Epub 2010 Feb 1.

21.

Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences.

Mizrahi A, Czerniak A, Levy T, Amiur S, Gallula J, Matouk I, Abu-lail R, Sorin V, Birman T, de Groot N, Hochberg A, Ohana P.

J Transl Med. 2009 Aug 6;7:69. doi: 10.1186/1479-5876-7-69.

22.

Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin.

Sidi AA, Ohana P, Benjamin S, Shalev M, Ransom JH, Lamm D, Hochberg A, Leibovitch I.

J Urol. 2008 Dec;180(6):2379-83. doi: 10.1016/j.juro.2008.08.006. Epub 2008 Oct 31.

PMID:
18950807
23.

Chemically induced bladder cancer--a sonographic and morphologic description.

Gofrit ON, Birman T, Dinaburg A, Ayesh S, Ohana P, Hochberg A.

Urology. 2006 Jul;68(1):231-5.

PMID:
16844461
24.

H19 expression in hepatic metastases from a range of human carcinomas.

Fellig Y, Ariel I, Ohana P, Schachter P, Sinelnikov I, Birman T, Ayesh S, Schneider T, de Groot N, Czerniak A, Hochberg A.

J Clin Pathol. 2005 Oct;58(10):1064-8.

25.

Regulatory sequences of H19 and IGF2 genes in DNA-based therapy of colorectal rat liver metastases.

Ohana P, Schachter P, Ayesh B, Mizrahi A, Birman T, Schneider T, Matouk I, Ayesh S, Kuppen PJ, de Groot N, Czerniak A, Hochberg A.

J Gene Med. 2005 Mar;7(3):366-74.

PMID:
15521051
26.

[Drug patents and other ways to protect pharmaceutical research].

Ohana P, Tardieu S, Blin O, Tassy S, Sambuc R.

Therapie. 2004 Mar-Apr;59(2):253-7. Review. French.

PMID:
15359623
27.

Oncofetal splice-pattern of the human H19 gene.

Matouk I, Ayesh B, Schneider T, Ayesh S, Ohana P, de-Groot N, Hochberg A, Galun E.

Biochem Biophys Res Commun. 2004 Jun 11;318(4):916-9.

PMID:
15147959
28.

Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences.

Ayesh B, Matouk I, Ohana P, Sughayer MA, Birman T, Ayesh S, Schneider T, de Groot N, Hochberg A.

Mol Ther. 2003 Apr;7(4):535-41.

29.

Possible physiological role of H19 RNA.

Ayesh S, Matouk I, Schneider T, Ohana P, Laster M, Al-Sharef W, De-Groot N, Hochberg A.

Mol Carcinog. 2002 Oct;35(2):63-74.

PMID:
12325036
30.

Use of H19 regulatory sequences for targeted gene therapy in cancer.

Ohana P, Bibi O, Matouk I, Levy C, Birman T, Ariel I, Schneider T, Ayesh S, Giladi H, Laster M, de Groot N, Hochberg A.

Int J Cancer. 2002 Apr 10;98(5):645-50.

31.

Imaging transgene expression in live animals.

Honigman A, Zeira E, Ohana P, Abramovitz R, Tavor E, Bar I, Zilberman Y, Rabinovsky R, Gazit D, Joseph A, Panet A, Shai E, Palmon A, Laster M, Galun E.

Mol Ther. 2001 Sep;4(3):239-49.

32.

Characterization of human and mouse H19 regulatory sequences.

Banet G, Bibi O, Matouk I, Ayesh S, Laster M, Kimber KM, Tykocinski M, de Groot N, Hochberg A, Ohana P.

Mol Biol Rep. 2000 Sep;27(3):157-65.

PMID:
11254105
33.

Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells.

Abdul-Ghani R, Ohana P, Matouk I, Ayesh S, Ayesh B, Laster M, Bibi O, Giladi H, Molnar-Kimber K, Sughayer MA, de Groot N, Hochberg A.

Mol Ther. 2000 Dec;2(6):539-44.

34.

The expression of the H19 gene and its function in human bladder carcinoma cell lines.

Ohana P, Kopf E, Bibi O, Ayesh S, Schneider T, Laster M, Tykocinski M, de Groot N, Hochberg A.

FEBS Lett. 1999 Jul 2;454(1-2):81-4.

35.

Three cdg operons control cellular turnover of cyclic di-GMP in Acetobacter xylinum: genetic organization and occurrence of conserved domains in isoenzymes.

Tal R, Wong HC, Calhoon R, Gelfand D, Fear AL, Volman G, Mayer R, Ross P, Amikam D, Weinhouse H, Cohen A, Sapir S, Ohana P, Benziman M.

J Bacteriol. 1998 Sep;180(17):4416-25.

36.

Identification of a novel triterpenoid saponin from Pisum sativum as a specific inhibitor of the diguanylate cyclase of Acetobacter xylinum.

Ohana P, Delmer DP, Carlson RW, Glushka J, Azadi P, Bacic T, Benziman M.

Plant Cell Physiol. 1998 Feb;39(2):144-52.

PMID:
9559560
37.

c-di-GMP-binding protein, a new factor regulating cellulose synthesis in Acetobacter xylinum.

Weinhouse H, Sapir S, Amikam D, Shilo Y, Volman G, Ohana P, Benziman M.

FEBS Lett. 1997 Oct 20;416(2):207-11.

38.

In Vitro Synthesis of Cellulose in Plants: Still a Long Way to Go!

Delmer DP, Ohana P, Gonen L, Benziman M.

Plant Physiol. 1993 Oct;103(2):307-308. No abstract available.

40.
41.

beta-Furfuryl-beta-glucoside. An endogenous activator of higher plant UDP-glucose: (1----3)-beta-glucan synthase.

Ohana P, Delmer DP, Steffens JC, Matthews DE, Mayer R, Benziman M.

J Biol Chem. 1991 Jul 25;266(21):13742-5.

42.

Polypeptide composition of bacterial cyclic diguanylic acid-dependent cellulose synthase and the occurrence of immunologically crossreacting proteins in higher plants.

Mayer R, Ross P, Weinhouse H, Amikam D, Volman G, Ohana P, Calhoon RD, Wong HC, Emerick AW, Benziman M.

Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5472-6.

Supplemental Content

Support Center